{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Martin-Broto J"],"funding":["Celgene"],"pagination":["6278"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9587294"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. In this multicenter, phase II trial (NCT03275818), patients with symptomatic/progressing DF received three cycles of weekly nab-paclitaxel. Brief pain inventory short form (BPI-SF) was collected at baseline and in every visit. MRI was performed every 3 months. Primary composite endpoint was RECIST 1.1 overall response rate (ORR) and/or clinical response (improvement ≥ 2 points in BPI-SF). If 40% of patients achieved clinical/radiological response, further investigation would be warranted. Toxicity, progression-free survival (PFS), pattern of response and its correlation with clinical best r"],"journal":["Nature communications"],"pubmed_title":["A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors."],"pmcid":["PMC9587294"],"funding_grant_id":["AX-CL-GEIS-007345"],"pubmed_authors":["Valverde C","Redondo A","Marcilla D","Moura DS","Martinez-Trufero J","Lopez-Martin JA","Gutierrez A","Ledesma P","Hindi N","Martinez-Marin V","Morales JM","Di Lernia D","Lopez-Pousa A","Diaz-Beveridge R","Zamora J","Martin-Broto J","Luna P","Arribas I"],"additional_accession":[]},"is_claimable":false,"name":"A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors.","description":"Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. In this multicenter, phase II trial (NCT03275818), patients with symptomatic/progressing DF received three cycles of weekly nab-paclitaxel. Brief pain inventory short form (BPI-SF) was collected at baseline and in every visit. MRI was performed every 3 months. Primary composite endpoint was RECIST 1.1 overall response rate (ORR) and/or clinical response (improvement ≥ 2 points in BPI-SF). If 40% of patients achieved clinical/radiological response, further investigation would be warranted. Toxicity, progression-free survival (PFS), pattern of response and its correlation with clinical best r","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-27T23:06:40.39Z","creation":"2025-02-18T23:29:39.374Z"},"accession":"S-EPMC9587294","cross_references":{"pubmed":["36271011"],"doi":["10.1038/s41467-022-33975-6"]}}